EP0944729A1 - Process for the production of penicillin g or v, cephalosporin g or v, and derivatives thereof - Google Patents

Process for the production of penicillin g or v, cephalosporin g or v, and derivatives thereof

Info

Publication number
EP0944729A1
EP0944729A1 EP97954433A EP97954433A EP0944729A1 EP 0944729 A1 EP0944729 A1 EP 0944729A1 EP 97954433 A EP97954433 A EP 97954433A EP 97954433 A EP97954433 A EP 97954433A EP 0944729 A1 EP0944729 A1 EP 0944729A1
Authority
EP
European Patent Office
Prior art keywords
penam
penicillin
producing
phenoxyacetyl
phenylacetyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97954433A
Other languages
German (de)
French (fr)
Inventor
Roelof Ary Lans Bovenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke DSM NV
Original Assignee
DSM NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM NV filed Critical DSM NV
Priority to EP97954433A priority Critical patent/EP0944729A1/en
Publication of EP0944729A1 publication Critical patent/EP0944729A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P37/00Preparation of compounds having a 4-thia-1-azabicyclo [3.2.0] heptane ring system, e.g. penicillin

Definitions

  • the present invention relates to the field of fermentative Mactam production.
  • /M_actam antibiotics constitute the most important group of antibiotic compounds, with a long history of clinical use. Among this group, the prominent ones are the penicillins and cephalosporins. These compounds are naturally produced by the filamentous fungi Penicillium chrysogenum and
  • the first two steps in the biosynthesis of penicillin in P. chrysogenum are the condensation of the three amino acids L-5-amino-5-carboxypentanoic acid (L- ⁇ -aminoadipic acid) (A), L-cysteine (C) and L-valine (V) into the tripeptide LLD-ACV, followed by cyclization of this tripeptide to form isopenicillin N.
  • L- ⁇ -aminoadipic acid A
  • L-cysteine C
  • L-valine V
  • This compound contains the typical /Mactam structure.
  • the third step involves the exchange of the hydrophilic D- ⁇ -aminoadipic acid side chain of L-5-amino-5-carboxypentanoic acid by a hydrophobic side chain, by the action of the enzyme acyltransferase (AT).
  • AT acyltransferase
  • the enzymatic exchange reaction mediated by AT takes place inside a cellular organelle, the microbody, as has been described in EP-A-04481 80.
  • the third step is the isomerization of isopenicillin N to penicillin N by an epimerase, whereupon the five-membered ring structure characteristic of penicillins is expanded by the enzyme expandase to the six-membered ring characteristic of cephalosporins.
  • V and penicillin G produced by adding the hydrophobic side chain precursors phenoxyacetic acid or phenylacetic acid, respectively, during fermentation of P. chrysogenum, thereby replacing the side chains of the natural /Mactams with phenoxyacetic acid or phenylacetic acid.
  • the present invention discloses that certain derivatives of phenylbutyric acid, i.e. phenylbutyric acid derivatives wherein the acyl chain is extended by pairs of carbon atoms and wherein specific substituents are present at the ⁇ and/or ⁇ - position of the acyl chain, are advantageously used as side chain precursors in the fermentative production of N-phenylacetyl penam or cephem compounds.
  • the present invention further discloses that the use of phenoxy derivatives of the specified phenylbutyric acid derivatives leads to production of N-phenoxyacetyl penam or cephem compounds.
  • the present invention discloses a process for the fermentative production of N-phenylacetyl or N-phenoxyacetyl penam or cephem compounds, wherein fermentation occurs in the presence of an ⁇ - and/or ( ⁇ /-1 )-substituted phenylalkanoic acid as a side chain precursor, said ⁇ - and/or ( -1 )-substituted phenylalkanoic acid having a structure according to formula 1 :
  • the upper limit of the carbon chain length of the phenylalkanoic acid is mainly determined by the efficiency by which the fatty acyl group is attacked by /?-oxidation.
  • n is an odd number from 1 up to 1 5.
  • n is an odd number from 1 up to 9, more preferably from 1 up to 5.
  • n is 1 .
  • 3-Benzoylpropionic acid is a preferred side chain precursor in the process of the invention, since this compound is conveniently synthesized from relatively cheap constituents (Sommerville and Allen, Org. Synth. Coll. Vol. II ( 1 943), 81 -83).
  • the present invention additionally envisages the production of cephalosporin G or V derivatives in a fermentation process applying the precursors according to the invention, by using recombinant penam or cephem- producing strains, i.e. recombinant P. chrysogenum or Acremonium chrysogenum strains.
  • recombinant penam or cephem- producing strains i.e. recombinant P. chrysogenum or Acremonium chrysogenum strains.
  • different cephalosporin G or V compounds are produced.
  • Deacetoxy cephalosporin G or V derivatives are produced by, for instance, a recombinant expandase-expressing P. chrysogenum strain, i.e. a P. chrysogenum strain provided with an expression cassette comprising an expandase gene (see EP 0532341 or WO95/04149 disclosing expandase- expressing P. chrysogenum strains).
  • a recombinant expandase-expressing P. chrysogenum strain i.e. a P. chrysogenum strain provided with an expression cassette comprising an expandase gene (see EP 0532341 or WO95/04149 disclosing expandase- expressing P. chrysogenum strains).
  • WO96/38580 is relevant since this document discloses that penicillin G can be expanded in vivo in an expandase-expressing P. chrysogenum strain.
  • a recombinant expandase-expressing P. chrysogenum strain is provided with one or more expression cassettes comprising additional relevant cephalosporin biosynthetic genes, such as a gene encoding hydroxylase and/or a gene encoding acetyl transferase, other cephalosporin G or V derivatives than deacetoxy compounds are produced.
  • cephalosporin G or V derivatives other than deacetoxy compounds are produced using an A. chrysogenum strain recombinantly expressing an acyltransferase gene.
  • the process of the invention is carried out by fermentation of a suitable penam- or cephem-producing strain, i.e. a fungal strain as defined above, in a suitable fermentation medium.
  • a suitable penam- or cephem-producing strain i.e. a fungal strain as defined above
  • the fermentation conditions which are used are not critical for the present invention, provided that the fermentation occurs in the presence of a phenyl- or phenoxybutyric acid derivative according to Formula 1 as a side chain precursor.
  • fermentation conditions can be applied such as disclosed in EP 0532341 .
  • the fermentatively produced penicillin G or V or cephalosporin G or V derivative is recovered from the fermentation broth using any suitable technology known to the skilled person.
  • the penicillin G or V or cephalosporin G or V derivative may be deacylated to form the corresponding deacylated penicillin, i.e. 6- aminopenicillanic acid (6-APA), or cephalosporin, e.g. 7-aminodeacetoxy- cephalosporanic acid (7-ADCA), 7-aminodeacetylcephalosporanic acid (7- ADAC) or 7-aminocephalosporanic acid (7-ACA) .
  • Deacylation is performed by any suitable means.
  • deacylation is performed in a one-step enzymatical process, using a suitable enzyme.
  • Suitable enzymes for deacylation of penicillin G or cephalosporin G derivatives are the acylases from E. coli or A. faecalis and for deacylation of penicillin V or cephalosporin V compounds the acylases from a fungal source, such as Fusarium.
  • an immobilized enzyme is used, in order to be able to use the enzyme repeatedly.
  • P. chrysogenum is fermented in a suitable culture medium in the presence of 3-benzoylpropionate as the side chain precursor. After separating off the biomass, the fermentation broth obtained is analyzed for the presence of penicillins, using HPLC and/or proton NMR. Penicillin G is shown to be the sole penicillin present in the fermentation broth. In addition, 3-benzoylpropionate is surprisingly shown to produce penicillin G more efficiently than phenylacetate does.
  • Precursor-solution 10 % (w/v) precursor adjusted to pH 6.5 with 1 M KOH, filter-sterilized before use.
  • a two-stage fermentation of the P. chrysogenum Wisconsin 54-1 255 strain in shake flasks was used for the production of penicillins.
  • the seed stage was initiated by adding 2 * 10 8 spores to 50ml/500ml flask of medium composed of (g/l): glucose, 30; (NH 4 ) 2 SO 4 , 10; KH 2 PO 4 , 10; trace element solution I (MgSO 4 .7H 2 O, 25; FeSO 4 .7H 2 O, 10; CuSO 4 .5H 2 O, 0.5; ZnSO 4 .7H 2 O, 2; Na 2 SO 4 , 50; MnSO 4 .H 2 O, 2; CaCI 2 .2H 2 O, 5), 10 (ml/I) (pH before sterilization 6.5).
  • medium composed of (g/l): glucose, 30; (NH 4 ) 2 SO 4 , 10; KH 2 PO 4 , 10; trace element solution I (MgSO 4 .7H 2
  • the seed culture is incubated for 48-72 hours at 25-30 °C and subsequently used to inoculate 10-20 volumes of a production medium containing (g/l): lactose, 80; maltose, 20; CaSO 4 , 4; urea, 3; MgSO 4 .7H 2 O, 2; KH 2 PO 4 , 7; NaCI, 0.5; (NH 4 ) 2 SO 4 , 6; FeSO 4 .7H 2 O, 0.1 ; trace element solution II (CuSO 4 .5H 2 O, 0.5; ZnSO 4 .7H 2 O, 2; MnSO 4 .H 2 O, 2; Na 2 SO 4 , 50);(pH before sterilization 5.5-6.0).
  • the precursor of choice solution 1
  • the incubation is then continued for another 1 20 hours.
  • Penicillium chrysogenum to utilize different side-chain precursors for pencillin production was examined. Phenylacetic acid, butyric acid, phenylbutyric acid and 3-benzoylpropionic acid were tested at final concentrations of 0.04% and 0.08% (w/v) . At the end of the production stage, culture filtrates were collected and examined by H-NMR.

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

The present invention discloses a fermentative process for the production of penicillin G or V or cephalosporin G or V derivatives wherein certain derivatives of phenylbutyric acid are used as a side chain precursor. In said phenylbutyric acid derivatives, the acyl chain is extended by pairs of carbon atoms and certain substituents are present at the φ- and/or φ-1 position. The corresponding phenoxybutyric acid derivatives are used to produce penicillin V or cephalosporin V derivatives. Optionally, the penicillin or cephalosporin G or V compounds are deacylated to produce their deacylated counterparts.

Description

PROCESS FOR THE PRODUCTION OF PENICILLIN G OR V, CEPHALOSPORIN G OR V, AND DERIVATIVES THEREOF
Field of the invention
The present invention relates to the field of fermentative Mactam production.
Background of the invention
/M_actam antibiotics constitute the most important group of antibiotic compounds, with a long history of clinical use. Among this group, the prominent ones are the penicillins and cephalosporins. These compounds are naturally produced by the filamentous fungi Penicillium chrysogenum and
Acremonium chrysogenum, respectively.
As a result of classical strain improvement techniques, the production levels of the antibiotics in Penicillium chrysogenum and Acremonium chrysogenum have increased dramatically over the past decades. With the increasing knowledge of the biosynthetic pathways leading to penicillins and cephalosporins, and the advent of recombinant DNA technology, new tools for the improvement of production strains and for the t7 vivo derivatization of the 5 compounds have become available.
Most enzymes involved in Mactam biosynthesis have been identified and their corresponding genes been cloned, as is decribed by Ingolia and Queener,
Med. Res. Rev. 9 ( 1 989), 245-264 (biosynthesis route and enzymes), and
Aharonowitz, Cohen, and Martin, Ann. Rev. Microbiol. 46 ( 1 992), 461 -495 0 (gene cloning).
The first two steps in the biosynthesis of penicillin in P. chrysogenum are the condensation of the three amino acids L-5-amino-5-carboxypentanoic acid (L-σ-aminoadipic acid) (A), L-cysteine (C) and L-valine (V) into the tripeptide LLD-ACV, followed by cyclization of this tripeptide to form isopenicillin N. This compound contains the typical /Mactam structure. These first two steps in the biosynthesis of penicillins are common in penicillin, cephamycin and cephalosporin producing fungi and bacteria.
The third step involves the exchange of the hydrophilic D-σ-aminoadipic acid side chain of L-5-amino-5-carboxypentanoic acid by a hydrophobic side chain, by the action of the enzyme acyltransferase (AT). The enzymatic exchange reaction mediated by AT takes place inside a cellular organelle, the microbody, as has been described in EP-A-04481 80.
In cephalosporin-producing organisms, the third step is the isomerization of isopenicillin N to penicillin N by an epimerase, whereupon the five-membered ring structure characteristic of penicillins is expanded by the enzyme expandase to the six-membered ring characteristic of cephalosporins.
The only directly fermented penicillins of industrial interest are penicillin
V and penicillin G, produced by adding the hydrophobic side chain precursors phenoxyacetic acid or phenylacetic acid, respectively, during fermentation of P. chrysogenum, thereby replacing the side chains of the natural /Mactams with phenoxyacetic acid or phenylacetic acid.
Next to phenylacetic acid, phenylbutyric acid and certain derivatives give rise to the production of penicillin G, although said acids produce penicillin G with a much lower efficiency than phenylacetic acid (Behrens et al., J. Biol.
Chem. 1 75 (1 948), 793-809; Arnstein and Grant, Bacteriol. Rev. 20 ( 1 956), 1 33-147) .
It is surprisingly shown by the present invention that specific derivatives of phenylbutyric acid give rise to the production of penicillin G with an even higher efficiency than phenylacetic acid. Description of the invention
The present invention discloses that certain derivatives of phenylbutyric acid, i.e. phenylbutyric acid derivatives wherein the acyl chain is extended by pairs of carbon atoms and wherein specific substituents are present at the ω and/or ω- position of the acyl chain, are advantageously used as side chain precursors in the fermentative production of N-phenylacetyl penam or cephem compounds.
The present invention further discloses that the use of phenoxy derivatives of the specified phenylbutyric acid derivatives leads to production of N-phenoxyacetyl penam or cephem compounds.
Specifically, the present invention discloses a process for the fermentative production of N-phenylacetyl or N-phenoxyacetyl penam or cephem compounds, wherein fermentation occurs in the presence of an ω- and/or (α/-1 )-substituted phenylalkanoic acid as a side chain precursor, said ω- and/or ( -1 )-substituted phenylalkanoic acid having a structure according to formula 1 :
wherein
-R, and -R3 are selected from the group consisting of -OH, = O or -H, where -R, and -R3 can be the same or different, with the proviso that -R, and -R3 are not both -H or = O,
-R2 or -R4, respectively, is -H if -R, or -R3, respectively, is -OH or -H, -R2 or -R4, respectively, is not present if -R or -R3, respectively, is = O, -R5 is -OR6 or -NH2, wherein R6 is selected from the group consisting of -H, -CH3 or -CH2CH3, m is 0 or 1 , n is an odd number from 1 up to 1 5, the carbon chain optionally containing on or more double bonds.
It is to be understood that the upper limit of the carbon chain length of the phenylalkanoic acid is mainly determined by the efficiency by which the fatty acyl group is attacked by /?-oxidation. Suitably, a chain length up to about
1 8 carbon atoms may be used, implicating that n is an odd number from 1 up to 1 5. Preferably, n is an odd number from 1 up to 9, more preferably from 1 up to 5. Most preferably, n is 1 . Preferably, -R., or -R3 is either = 0 or -OH implicating that -R2 or -R4 is either not present or -H, -R3 and -R4 are -H, -R5 is -OH, m is 0 or 1 and n is 1 .
More preferably -R, is either = O or -OH implicating that -R2 is either not present or -H, -R3 and -R4 are -H, -R5 is -OR6, wherein R6 is -H, m is 0 or 1 and n is 1 . Most preferably, 3-benzoylpropionic acid is used as a side chain precursor, i.e. R is = O, R2 is not present, R3 and R4 are -H, R5 is -OH, m is 0 and n is 1 .
3-Benzoylpropionic acid is a preferred side chain precursor in the process of the invention, since this compound is conveniently synthesized from relatively cheap constituents (Sommerville and Allen, Org. Synth. Coll. Vol. II ( 1 943), 81 -83).
When using a P. chrysogenum strain in the process of the invention, penicillin G or V are produced.
It is shown that the phenylbutyric acid derivative 3-benzoylpropionic acid gives rise to the production of penicillin G with a much higher efficiency than phenylbutyric acid and, more importantly, with an even higher efficiency than phenylacetic acid.
The present invention additionally envisages the production of cephalosporin G or V derivatives in a fermentation process applying the precursors according to the invention, by using recombinant penam or cephem- producing strains, i.e. recombinant P. chrysogenum or Acremonium chrysogenum strains. Depending on the specific recombinant strain which is used in the fermentation process according to the invention, different cephalosporin G or V compounds are produced.
Deacetoxy cephalosporin G or V derivatives are produced by, for instance, a recombinant expandase-expressing P. chrysogenum strain, i.e. a P. chrysogenum strain provided with an expression cassette comprising an expandase gene (see EP 0532341 or WO95/04149 disclosing expandase- expressing P. chrysogenum strains). In that regard, WO96/38580 is relevant since this document discloses that penicillin G can be expanded in vivo in an expandase-expressing P. chrysogenum strain.
If a recombinant expandase-expressing P. chrysogenum strain is provided with one or more expression cassettes comprising additional relevant cephalosporin biosynthetic genes, such as a gene encoding hydroxylase and/or a gene encoding acetyl transferase, other cephalosporin G or V derivatives than deacetoxy compounds are produced. Alternatively, cephalosporin G or V derivatives other than deacetoxy compounds are produced using an A. chrysogenum strain recombinantly expressing an acyltransferase gene.
The process of the invention is carried out by fermentation of a suitable penam- or cephem-producing strain, i.e. a fungal strain as defined above, in a suitable fermentation medium. The fermentation conditions which are used are not critical for the present invention, provided that the fermentation occurs in the presence of a phenyl- or phenoxybutyric acid derivative according to Formula 1 as a side chain precursor. For instance, fermentation conditions can be applied such as disclosed in EP 0532341 .
Subsequent to the fermentation process, the fermentatively produced penicillin G or V or cephalosporin G or V derivative is recovered from the fermentation broth using any suitable technology known to the skilled person.
Optionally, the penicillin G or V or cephalosporin G or V derivative may be deacylated to form the corresponding deacylated penicillin, i.e. 6- aminopenicillanic acid (6-APA), or cephalosporin, e.g. 7-aminodeacetoxy- cephalosporanic acid (7-ADCA), 7-aminodeacetylcephalosporanic acid (7- ADAC) or 7-aminocephalosporanic acid (7-ACA) . Deacylation is performed by any suitable means. Preferably, deacylation is performed in a one-step enzymatical process, using a suitable enzyme. Suitable enzymes for deacylation of penicillin G or cephalosporin G derivatives are the acylases from E. coli or A. faecalis and for deacylation of penicillin V or cephalosporin V compounds the acylases from a fungal source, such as Fusarium. Preferably, an immobilized enzyme is used, in order to be able to use the enzyme repeatedly. In a preferred embodiment of the invention, P. chrysogenum is fermented in a suitable culture medium in the presence of 3-benzoylpropionate as the side chain precursor. After separating off the biomass, the fermentation broth obtained is analyzed for the presence of penicillins, using HPLC and/or proton NMR. Penicillin G is shown to be the sole penicillin present in the fermentation broth. In addition, 3-benzoylpropionate is surprisingly shown to produce penicillin G more efficiently than phenylacetate does.
Example 1 Production of penicillin G using
3-benzoylpropionic acid as the side chain precursor
Strains used Penicillium chrysogenum Wisconsin 54-1255 (ATCC 28089)
Solutions
Precursor-solution: 10 % (w/v) precursor adjusted to pH 6.5 with 1 M KOH, filter-sterilized before use.
Growth conditions
A two-stage fermentation of the P. chrysogenum Wisconsin 54-1 255 strain in shake flasks was used for the production of penicillins. The seed stage was initiated by adding 2 * 108 spores to 50ml/500ml flask of medium composed of (g/l): glucose, 30; (NH4)2SO4, 10; KH2PO4, 10; trace element solution I (MgSO4.7H2O, 25; FeSO4.7H2O, 10; CuSO4.5H2O, 0.5; ZnSO4.7H2O, 2; Na2SO4, 50; MnSO4.H2O, 2; CaCI2.2H2O, 5), 10 (ml/I) (pH before sterilization 6.5).
The seed culture is incubated for 48-72 hours at 25-30 °C and subsequently used to inoculate 10-20 volumes of a production medium containing (g/l): lactose, 80; maltose, 20; CaSO4, 4; urea, 3; MgSO4.7H2O, 2; KH2PO4, 7; NaCI, 0.5; (NH4)2SO4, 6; FeSO4.7H2O, 0.1 ; trace element solution II (CuSO4.5H2O, 0.5; ZnSO4.7H2O, 2; MnSO4.H2O, 2; Na2SO4, 50);(pH before sterilization 5.5-6.0). The precursor of choice (solution 1 ) is added to the indicated concentration. The incubation is then continued for another 1 20 hours.
The ability of Penicillium chrysogenum to utilize different side-chain precursors for pencillin production was examined. Phenylacetic acid, butyric acid, phenylbutyric acid and 3-benzoylpropionic acid were tested at final concentrations of 0.04% and 0.08% (w/v) . At the end of the production stage, culture filtrates were collected and examined by H-NMR.
When no precursor was added the main Mactams that accumulated in the medium were 6-aminopenicillanic acid and isopenicillin N. Addition of either phenylacetic acid, phenylbutyric acid or 3-benzoylpropionic acid resulted in the sole production of penicillin G (Table 1 ). The highest production of penicillin G was obtained using 0.08% (w/v) 3-benzoylpropionic acid.
Table 1 Penicillin production with different side-chain precursors
determined by H-NMR Relative to the production of penicillin G at an initial phenylacetic acid concentration of 0.04% (w/v)

Claims

Claims
1 . A process for producing an N-phenylacetyl or an N-phenoxyacetyl penam or cephem compound, optionally including deacylating said N-phenylacetyl or N-phenoxyacetyl penam or cephem compound, comprising the steps of: * fermenting a suitable penam- or cephem-producing strain in a fermentation medium in the presence of a side chain precursor according to formula 1
wherein - -R1 and -R3 are selected from the group consisting of -OH, = 0 or -H, where -R., and -R3 can be the same or different, with the proviso that -R, and -R3 are not both -H or = 0,
-R2 or -R4, respectively, is -H if -R, or -R3, respectively, is -OH or -H, -R2 or -R4, respectively, is not present if -R, or -R3, respectively, is = O, - -R5 is -OR6 or -NH2, wherein R6 is selected from the group consisting of -H, -CH3 or -CH2CH3, m is 0 or 1 , n is an odd number from 1 up to 1 5, the carbon chain optionally containing on or more double bonds, and * recovering the produced N-phenylacetyl or N-phenoxyacetyl penam or cephem compound from the fermentation broth, and
* optionally deacylating the produced N-phenylacetyl or N-phenoxyacetyl penam or cephem compound and recovering the corresponding deacylated penam or cephem compound.
2. A process according to claim 1 producing an N-phenylacetyl penam or cephem compound wherein fermentation is performed using a side chain precursor according to formula 1 wherein m is 0.
3. A process according to claim 2, wherein fermentation is performed using a side chain precursor according to formula 1 wherein R^ is = O, R3 and R4 are -H, R5 is -OH, m is 0 and n is 1 .
4. A process according to claim 1 producing an N-phenoxyacetyl penam or cephem compound wherein fermentation is performed using a side chain precursor according to formula 1 wherein m is 1 .
5. A process according to any one of the claims 1 -4 producing an N- phenylacetyl or an N-phenoxyacetyl penam compound, wherein the penam or cephem-producing strain is Penicillium chrysogenum and the N-phenylacetyl or N-phenoxyacetyl penam compound is penicillin G or V.
6. A process according to claim 5, wherein penicillin G or V is deacylated producing 6-APA.
7. A process according to any one of the claims 1 -4 producing an N- phenylacetyl or an N-phenoxyacetyl cephem compound, wherein the penam or cephem-producing strain is a recombinant Penicillium chrysogenum strain expressing expandase and the N-phenylacetyl or N-phenoxyacetyl cephem compound is a cephalosporin G or V derivative.
8. A process according to claim 7, wherein the cephalosporin G or V derivative is deacylated producing 7-ADCA, 7-ADAC or 7-ACA.
EP97954433A 1996-12-16 1997-12-15 Process for the production of penicillin g or v, cephalosporin g or v, and derivatives thereof Withdrawn EP0944729A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP97954433A EP0944729A1 (en) 1996-12-16 1997-12-15 Process for the production of penicillin g or v, cephalosporin g or v, and derivatives thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP96203544 1996-12-16
EP96203544 1996-12-16
EP97954433A EP0944729A1 (en) 1996-12-16 1997-12-15 Process for the production of penicillin g or v, cephalosporin g or v, and derivatives thereof
PCT/EP1997/007153 WO1998027221A1 (en) 1996-12-16 1997-12-15 Process for the production of penicillin g or v, cephalosporin g or v, and derivatives thereof

Publications (1)

Publication Number Publication Date
EP0944729A1 true EP0944729A1 (en) 1999-09-29

Family

ID=8224700

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97954433A Withdrawn EP0944729A1 (en) 1996-12-16 1997-12-15 Process for the production of penicillin g or v, cephalosporin g or v, and derivatives thereof

Country Status (8)

Country Link
EP (1) EP0944729A1 (en)
JP (1) JP2001506131A (en)
KR (1) KR20000057579A (en)
AU (1) AU5858698A (en)
BR (1) BR9713579A (en)
ID (1) ID22234A (en)
PL (1) PL333912A1 (en)
WO (1) WO1998027221A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208481A (en) * 1978-11-16 1980-06-17 E. R. Squibb & Sons, Inc. Use of phenylalkanes as precursors in benzylpenicillin fermentation
US4250258A (en) * 1979-12-20 1981-02-10 E. R. Squibb & Sons, Inc. Use of phenoxyalkanes as precursors in penicillin V fermentation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9827221A1 *

Also Published As

Publication number Publication date
JP2001506131A (en) 2001-05-15
KR20000057579A (en) 2000-09-25
WO1998027221A1 (en) 1998-06-25
AU5858698A (en) 1998-07-15
ID22234A (en) 1999-09-23
BR9713579A (en) 2000-03-14
PL333912A1 (en) 2000-01-31

Similar Documents

Publication Publication Date Title
RU2208644C2 (en) Method for preparing n-deacylated cephalosporin
JP3027847B2 (en) New biochemical method for producing 7-ADCA
CN1301303A (en) Improved i(in vivo) production of cephalosporins
EP0828850B1 (en) Process for the production of 7-adca via expandase activity on penicillin g
EP1188838A1 (en) Method for producing 7-aminodesacetoxycephalosporanic acid (7-adca)
RU2208643C2 (en) Method for preparing n-deacylated cephalosporin
US5919680A (en) Process for the production of SSC's via expandase activity on penicillin G
EP0944729A1 (en) Process for the production of penicillin g or v, cephalosporin g or v, and derivatives thereof
KR100421225B1 (en) Process for the production of 7-adca via expandase activity on penicillin g
MXPA99005545A (en) Process for the production of penicillin g or v, cephalosporin g or v, and derivatives thereof
CN1240485A (en) Process for the production of pencillin G or V, cepholsporin G or V, and derivatives thereof
MXPA98010757A (en) Process for the fermentative production of deacylated cephalosporins
MXPA98010758A (en) Process for the fermentative production of deacylated cephalosporins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990614

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19990614;LT PAYMENT 19990614;LV PAYMENT 19990614;MK PAYMENT 19990614;RO PAYMENT 19990614;SI PAYMENT 19990614

17Q First examination report despatched

Effective date: 20011005

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020216